Advanced search
Publication Cover
Future Science OA Volume 7, 2021 - Issue 6
Submit an article Journal homepage
808
Views
5
CrossRef citations to date
0
Altmetric
Editorial

The Use of 68Ga prostate-specific Membrane Antigen PET-CT in Prostate Cancer: Diagnostic Challenges and Therapeutic Opportunities

Elisena Franzese1 Medical Oncology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, PozzuoliItaly
,
Stefano De Falco1 Medical Oncology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, PozzuoliItaly
,
Maria Maddalena Laterza1 Medical Oncology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, PozzuoliItaly
,
Liliana Montella1 Medical Oncology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, PozzuoliItaly
,
Sergio Facchini2 Department of Precision Medicine, University of Campania ‘Luigi Vanvitelli’NapoliCampaniaItaly
,
Carmela Liguori1 Medical Oncology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, PozzuoliItaly
,
Paola Coppola1 Medical Oncology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, PozzuoliItaly
,
Ylenia Diessa1 Medical Oncology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, PozzuoliItaly
,
Massimiliano Berretta3 Unit of Infectious Diseases, Department of Clinical & Experimental Medicine, University of Messina, MessinaItaly
,
Salvatore Pisconti4 Oncology Unit, SG Moscati Hospital, TarantoItaly
,
Francesco Trama5 Andrology & Urogynecological clinic, Santa Maria Terni Hospital, Terni, University of Perugia, PerugiaItaly
,
Matteo Ferro6 Division of Urology, European Institute of Oncology, Milan, 20141, Italy
,
Felice Crocetto7 Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, NaplesItaly
,
Morena Fasano2 Department of Precision Medicine, University of Campania ‘Luigi Vanvitelli’NapoliCampaniaItaly
,
Carlo Buonerba8 Department of Oncology & Hematology, Regional Reference Center for Rare Tumors, Department of Oncology & Hematology, AOU Federico II of Naples, Naples, 80131, Italy;9 National Reference Center for Environmental Health, Zoo-prophylactic Institute of Southern Italy, Portici, 80055, ItalyCorrespondence[email protected]
&
Gaetano Facchini1 Medical Oncology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, PozzuoliItaly
 show all
Article: FSO705 | Received 12 Mar 2021, Accepted 17 Mar 2021, Published online: 07 Apr 2021

References

  • SungH , FerlayJ , SiegelRLet al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. (2021).
  • SwamiU , McFarlandTR , NussenzveigR , AgarwalN. Advanced prostate cancer: treatment advances and future directions. Trends Cancer6(8), 702–715 (2020).
  • ChangSS. Overview of prostate-specific membrane antigen. Rev. Urol.6(Suppl. 10), S13–S18 (2004).
  • PastorinoS , RiondatoM , UccelliLet al.Toward the discovery and development of psma targeted inhibitors for nuclear medicine applications. Curr. Radiopharm.13(1), 63–79 (2020).
  • ScherHI , MorrisMJ , StadlerWMet al.Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J. Clin. Oncol.34(12), 1402–1418 (2016).
  • HofmanMS , LawrentschukN , FrancisRJet al.Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet395(10231), 1208–1216 (2020).
  • FendlerWP , CalaisJ , EiberMet al.Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol.5(6), 856–863 (2019).
  • HopeTA , GoodmanJZ , AllenIE , CalaisJ , FendlerWP , CarrollPR. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J. Nucl. Med.60(6), 786–793 (2019).
  • ZachoHD , RavnS , Afshar-OromiehA , FledeliusJ , EjlersenJA , PetersenLJ. Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous (99m)Tc bone scintigraphy. EJNMMI Res.10(1), 31 (2020).
  • YildirimÖA , GündoğanC , CanC , PoyrazK , ErdurE , KömekH. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients. Ann. Nucl. Med.35 (2021).
  • AksuA , KarahanŞen NP , TunaEB , AslanG , ÇapaKaya G. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients. Nucl. Med. Commun. (2021).
  • AlbertsIL , SeideSE , MingelsCet al.Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur. J. Nucl. Med. Mol. Imaging. (2021).
  • KyriakopoulosCE , ChenYH , CarducciMAet al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized Phase III E3805 chaarted trial. J. Clin. Oncol.36(11), 1080–1087 (2018).
  • BuonerbaC , FerroM , DolcePet al.Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol.151, 1–9 (2020).
  • DiLorenzo G , BuonerbaC. Oligometastatic prostate cancer: is it only a matter of perspective?Eur. Urol.75(5), 705–706 (2019).
  • TriggianiL , MazzolaR , MagriniSMet al.Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J. Urol.37(12), 2631–2637 (2019).
  • MoriK , MostafaeiH , PradereBet al.Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int. J. Clin. Oncol.25(11), 1892–1900 (2020).
  • BuonerbaC , PondGR , SonpavdeGet al.Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Futur. Oncol.9(6), 889–897 (2013).
  • DiLorenzo G , D'anielloC , BuonerbaCet al.Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs24(1), 84–89 (2013).
  • HofmanMS , EmmettL , SandhuSet al.[177Lu]-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, Phase II trial. Lancet397(10276), 797–804 (2021).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.